Samsung Biologics Moore: A Big Win!

📘 Samsung Biologics Chooses Rockville — And Maryland Quietly Reclaims Its Crown as America’s High‑Tech Bioscience Capital

By Maryland Wire Staff

Rockville didn’t just win a factory.

It won a declaration.

When Samsung Biologics — one of the world’s most powerful contract development and manufacturing organizations (CDMOs) — announced it would acquire GSK’s Rockville biologics campus for $280 million, the headlines focused on the global footprint, the investment, the technology. But the real story is far more local, far more strategic, and far more defining for Maryland’s economic identity.

This is a story about retaining more than 500 high‑skill jobs, expanding a sector that already employs tens of thousands, and sending a message to the rest of the country:

Maryland is not just in the bioscience race — it intends to lead it.

Sources confirm Samsung will keep the entire workforce in place, with additional hiring expected as the company upgrades and expands the site.

A Win That Could Have Gone South — Literally

State officials have been blunt: Maryland was not the only bidder.

Samsung could have taken this investment to lower‑cost states — South Carolina among them — where wages run 10–15% lower and land is cheaper.

But they didn’t.

Governor Moore with the “Greek Uncle” Clem Kaikis

Why?

Because Maryland has something no incentive package can replic with ate:

a deep, ready, highly trained bioscience workforce.

Montgomery County alone sits atop a talent reservoir fed by NIH, FDA, Johns Hopkins, UMBC, Montgomery College’s biotech pipeline, and decades of CDMO experience. Companies like Fisher BioServices/Thermo Fisher, Lonza, Catalent, AstraZeneca, and Emergent built the region into a manufacturing powerhouse long before “biotech” became a political buzzword.

Samsung didn’t come here for subsidies.

They came here for people.

The Boston Question: Has Maryland Quietly Overtaken the CDMO Corridor?

Boston’s Kendall Square gets the glamour.

But CDMO manufacturing — the backbone of biologics production — is not built on glamour. It’s built on:

• - GMP manufacturing expertise

• - Regulatory literacy

• - Tech‑transfer experience

• - A stable, credentialed workforce

• - Proximity to federal regulators

And on those metrics, Maryland is not just competitive — it’s formidable.

Samsung’s move signals something industry insiders have whispered for years:

Maryland is the East Coast’s true CDMO capital.

Boston dominates discovery.

Maryland dominates development, scale‑up, and manufacturing.

With Samsung joining AstraZeneca’s $2 billion expansion in Frederick/Gaithersburg, the state now hosts one of the densest clusters of biologics production capacity in the nation.

This is not a challenger brand.

This is a flagship.

A Workforce Built Over Decades — And Still Growing

Your memory of “10,000 jobs under multiple corporate names” is not nostalgia — it’s history.

Maryland’s CDMO ecosystem has always been layered:

• - Fisher BioServices / Thermo Fisher Scientific

• - Human Genome Sciences (now part of GSK)

• - AstraZeneca biologics manufacturing

• - Emergent BioSolutions

• - Lonza’s regional operations

• - Catalent’s Maryland footprint

Samsung is not creating a new industry here.

They are plugging into a mature one.

And that maturity is exactly why they chose Maryland.

Governor Moore’s Role — As Reported

According to reporting from WFMD and state releases, the deal followed direct engagement between Samsung Biologics executives, Governor Moore, and Maryland Commerce Secretary Harry Coker during an international trade mission to Japan and South Korea.

• State officials say the message was simple:

• Maryland has the workforce.

• Maryland has the infrastructure.

• Maryland has the regulatory adjacency.

• And Maryland is ready to compete globally.

Samsung agreed.

The company will retain more than 500 employees and expand operations — a validation of the state’s pitch and a tangible win for the administration’s economic development strategy.

Why This Matters for Maryland’s Future

Samsung’s arrival is not just a headline.

It is a signal.

1. Maryland is now a must‑have node in global biomanufacturing.

Samsung’s global network spans Korea, Europe, and now Rockville — a strategic U.S. anchor.

2. It stabilizes and grows a workforce that has been built over 30 years.

Retaining 500+ jobs is not maintenance — it’s momentum.

3. It positions Maryland as the safest bet for companies needing talent on Day One.

The state’s bioscience workforce is not theoretical.

It’s operational.

4. It strengthens Maryland’s claim as America’s high‑tech bioscience capital.

• Not by marketing.

• By manufacturing.

• The Bottom Line

Samsung Biologics didn’t just choose Maryland.

• They validated it.

• In an era when states fight tooth‑and‑nail for high‑skill jobs, Maryland won a global competition — not by being the cheapest, but by being the most capable.

• This is what economic identity looks like.

• This is what a bioscience capital looks like.

And this is what it looks like when a state bets on talent — and the world bets back.